Arvinas, Inc. (ARVN) Stock Grade

About Arvinas, Inc.'s fundamentals

Arvinas is a biotechnology company with a market capitalization of $769.7 million that reported a net loss in its latest annual period, resulting in a negative net margin of -30.8%. Revenue declined slightly year-over-year by 0.3%, indicating minimal topline growth. The company does not pay a dividend, and profitability metrics like P/E ratio and return on equity are not applicable due to the company's unprofitable status. As a pre-profitability biotech firm, Arvinas' financial performance reflects the typical cash burn characteristic of companies in early-stage drug development.